相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction
Dana Drzayich Antol et al.
ADVANCES IN THERAPY (2018)
From Molecules to Markets Broadening the Focus of Cardiovascular Innovation
Nalini A. Colaco et al.
CIRCULATION-HEART FAILURE (2018)
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure
Lindsey R. Sangaralingham et al.
CIRCULATION-HEART FAILURE (2018)
Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany
Rolf Wachter et al.
POSTGRADUATE MEDICINE (2018)
Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures
Patricia M. Danzon
VALUE IN HEALTH (2018)
Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
Rosa Ahn et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States
Adam D. DeVore et al.
CIRCULATION-HEART FAILURE (2018)
Insights into implementation of sacubitril/valsartan into clinical practice
Pieter Martens et al.
ESC HEART FAILURE (2018)
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context
Lucia S. D'Angiolella et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
Pierpaolo Pellicori et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Clyde W. Yancy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands
Simon van der Pol et al.
VALUE IN HEALTH (2017)
Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives
Bertram Pitt et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2017)
Limitations of Sacubitril/Valsartan in the Management of Heart Failure
Srikanth Yandrapalli et al.
AMERICAN JOURNAL OF THERAPEUTICS (2017)
Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
Alexander T. Sandhu et al.
ANNALS OF INTERNAL MEDICINE (2016)
Pharmaceutical Policy Reform - Balancing Affordability with Incentives for Innovation
Rena M. Conti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sacubitril-Valsartan for the Treatment of Heart Failure Effectiveness and Value
Daniel A. Ollendorf et al.
JAMA INTERNAL MEDICINE (2016)
Neprilysin Inhibition in the Time of Precision Medicine
Arthur M. Feldman
JACC-HEART FAILURE (2016)
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
Thomas A. Gaziano et al.
JAMA CARDIOLOGY (2016)
New Math on Drug Cost-Effectiveness
Peter B. Bach
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
HEART FAILURE Aldosterone antagonists are underused by clinicians
Jane-Lise Samuel et al.
NATURE REVIEWS CARDIOLOGY (2010)
分享论文
